Beckley Psytech has raised $18.6 million to advance 5-MeO-DMT (and third-generation follow-ups) through trials and hopes to have it be approved by 2025. Investors in the current round include Noetic and Bail Capital.
Compound 5-MeO-DMT
Visit article
Companies Featured
Beckley PsytechBeckley Psytech is working on getting 5-MeO-DMT to market as the first of a variety of psychedelic medicines.
Noetic
Noetic is a prolific psychedelic venture fund that invests in startups in the wellness and psychedelic space.
People Featured
Cosmo Feilding MellenCosmo Feilding Mellen is the Director & CEO of Beckley PsyTech. Previously he worked at the Beckley Foundation (with his mother Amanda Feilding) and co-founded Beckley Canopy Therapeutics.
Article Author
Josh HardmanJosh Hardman is the mind behind Psychedelic Alpha, and one of the leading writers covering the implementation of psychedelics as medicine.